NDAORALCAPSULE
Approved
May 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
ELDEPRYL (selegiline hydrochloride) by Gen Pharmaceuticals is clinical pharmacology the mechanisms accounting for selegiline's beneficial adjunctive action in the treatment of parkinson's disease are not fully understood. First approved in 1996.
Drug data last refreshed 16h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ELDEPRYL (selegiline hydrochloride) is an oral small-molecule MAO-B inhibitor used as an adjunctive treatment in Parkinson's disease to enhance dopaminergic activity. It works by irreversibly inhibiting monoamine oxidase type B, selectively blocking the breakdown of dopamine in the brain while preserving gut MAO-A activity to minimize hypertensive risks. The drug extends the efficacy of levodopa therapy in mid-to-late stage Parkinson's patients.
LOE Approaching
Product approaching end-of-life with moderate competitive pressure (30/100); brand team likely focused on lifecycle extension and managed transition to generic era.
Mechanism of Action
CLINICAL PHARMACOLOGY The mechanisms accounting for selegiline's beneficial adjunctive action in the treatment of Parkinson's disease are not fully understood. Inhibition of monoamine oxidase, type B, activity is generally considered to be of primary importance; in addition, there is evidence that…
Worked on ELDEPRYL at Gen Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.